| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Net income | -31.4 | -41.9 |
| EPS (diluted, $ a share) | $-0.88 | $-1.50 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, NASDAQ: TRAX. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
First Tracks Biotherapeutics, Inc.: key numbers
- Share price
- $46.56Close, Nov 16
- Market cap
- $1.96B
- Shares outstanding
- 42.02MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from First Tracks Biotherapeutics, Inc.
All →First Tracks Biotherapeutics Financial Results
First Tracks Biotherapeutics reported Q3 2026 financial results, highlighting a pro forma cash position of $343 million following a $200 million private placement. The company reported positive Phase 1b data for its lead candidate ANB033 in celiac disease and plans to initiate late-stage clinical development in 2027.
“ANB033, a subcutaneously administered CD122 antagonist designed to inhibit signaling of both IL-15 and IL-2 on immune cells, demonstrated statistically significant protection against gluten-induced intestinal damage and symptoms and was well tolerated in the Phase 1b gluten-challenge cohort. These data support our plans to progress ANB033 into late-stage development in 2027 in celiac disease as a potential treatment to prevent both acute symptoms and intestinal damage from gluten exposure despite general adherence to a gluten-free diet.”
Daniel Faga, president and chief executive officer
First Tracks Biotherapeutics Capital Raise
First Tracks Biotherapeutics, Inc. closed a private placement of 6,106,870 shares of common stock on October 19, 2026. In connection with the closing, the company entered into a registration rights agreement requiring it to file a resale registration statement for the investors within 30 days.
First Tracks Biotherapeutics Capital Raise of $200M
First Tracks Biotherapeutics entered into a securities purchase agreement for a $200 million private placement (PIPE) of 6,106,870 shares of common stock at $32.75 per share. The offering includes participation from several institutional investors and is intended to fund the clinical development of ANB033 and other general corporate purposes.
- Value
- $200M
- Counterparty
- Affinity Asset Advisors, LLC, First Light Asset Management, Sirenia Capital Management LP, TCGX, Trails Edge Capital Partners, Vestal Point Capital
First Tracks Biotherapeutics Clinical Trial Data
First Tracks Biotherapeutics announced positive topline data from the first Phase 1b cohort of its drug candidate ANB033 for the treatment of Celiac Disease. The company also updated its corporate investor presentation to reflect these clinical developments.